Please assess the completion status of the following clinical trial:

Trial Title: Preventing COVID-19 Complications With Low- and High-dose Anticoagulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: adult patient with COVID-19 infections, admitted to:~* an acute non-critical medical ward with admission D-dimer levels \>1,000ng/mL, or~* an acute critical ward (ICU, intermediate care unit)~Exclusion Criteria:~* ongoing or planned therapeutic anticoagulation for any other indication~* contra-indication to therapeutic anticoagulation~* hypersensitivity to heparin~* personal history of heparin-induced thrombocytopenia~* suspected or confirmed bacterial endocarditis~* bleeding events or tendency due to a suspected or confirmed hemostatic bleeding disorder~* organic lesion prone to bleeding~* platelet count \<50G/L, Hb level \<80g/L~* ongoing or recent (\<30 days) major bleeding, ischemic stroke, trauma, surgery~* use of dual antiplatelet therapy~* pregnancy~* bodyweight \<40kg or \>150kg.~* end of life care setting~* unwillingness to consent~* ongoing participation in a COVID-19 randomized clinical trial testing another therapeutic intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic anticoagulation (Type: EXPERIMENTAL): Participants will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or intravenous unfractionated heparin, from admission until the end of hospital stay or clinical recovery.
- Prophylactic anticoagulation (Type: ACTIVE_COMPARATOR): Participants will be treated with prophylactic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or unfractionated heparin, from admission until the end of hospital stay or clinical recovery. If hospitalized in the intensive care unit, they will receive an augmented thromboprophylaxis regimen as standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).